Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04621435 · ClinicalTrials.gov registry record · Phase 1
Imaging of Solid Tumors Using FAP-2286
A Phase 1 study of Metastatic Cancer and Solid Tumors, Adult, sponsored by Thomas Hope.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 191
- Enrollment target
- 1
- Study location
NCT04621435 is a Phase 1 study of Metastatic Cancer and Solid Tumors, Adult that is actively recruiting participants, run by Thomas Hope. The registered enrollment target is 191 participants, below the 442-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04621435, a Phase 1 study of Metastatic Cancer and Solid Tumors, Adult, is actively recruiting participants, sponsored by Thomas Hope.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 191 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.
Conditions Studied
Interventions
- DRUG Gallium-68 labelled (68Ga-) FAP-2286
- PROCEDURE Positron Emission Tomography (PET) imaging
- DRUG Copper-64 labeled (64Cu-) FAP-2286
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2020-12-14 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04621435
The ClinicalTrials.gov registry entry for NCT04621435 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 442-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (57% lower). The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Gallium-68 labelled (68Ga-) FAP-2286 is the first listed.
NCT04621435 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04621435 about?
NCT04621435 is a clinical study titled "Imaging of Solid Tumors Using FAP-2286". This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast A...
What is the current status of trial NCT04621435?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 191 participants. The study started on 2020-12-14. Estimated completion is 2026-12-31.
What conditions does trial NCT04621435 study?
This clinical trial studies the following conditions: Metastatic Cancer, Solid Tumors, Adult.
What interventions are being tested in trial NCT04621435?
The interventions under investigation include: Gallium-68 labelled (68Ga-) FAP-2286 (DRUG), Positron Emission Tomography (PET) imaging (PROCEDURE), Copper-64 labeled (64Cu-) FAP-2286 (DRUG).
Who is sponsoring clinical trial NCT04621435?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04621435 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RECRUITING · Phase 1
-
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.